Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Navigating from cellular phenotypic screen to clinical candidate: selective targeting of the NLRP3 inflammasome.
Matico R, Grauwen K, Chauhan D, Yu X, Abdiaj I, Adhikary S, Adriaensen I, Aranzazu GM, Alcázar J, Bassi M, Brisse E, Cañellas S, Chaudhuri S, Delgado F, Diéguez-Vázquez A, Du Jardin M, Eastham V, Finley M, Jacobs T, Keustermans K, Kuhn R, Llaveria J, Leenaerts J, Linares ML, Martín ML, Martín-Pérez R, Martínez C, Miller R, Muñoz FM, Muratore ME, Nooyens A, Perez-Benito L, Perrier M, Pietrak B, Serré J, Sharma S, Somers M, Suarez J, Tresadern G, Trabanco AA, Van den Bulck D, Van Gool M, Van Hauwermeiren F, Varghese T, Vega JA, Youssef SA, Edwards MJ, Oehlrich D, Van Opdenbosch N. Matico R, et al. Among authors: perrier m. EMBO Mol Med. 2025 Jan;17(1):54-84. doi: 10.1038/s44321-024-00181-4. Epub 2024 Dec 9. EMBO Mol Med. 2025. PMID: 39653810 Free article.
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET).
Walter T, Lecomte T, Hadoux J, Niccoli P, Saban-Roche L, Gaye E, Guimbaud R, Baconnier M, Hautefeuille V, Do Cao C, Petorin C, Hentic O, Perrier M, Aparicio T, Scoazec JY, Bonjour M, Gibert B, Hervieu V, Poncet D, Barritault M, Gerard L, Durand A; “Groupe d’étude des tumeurs endocrines (GTE)” and the French ENDOCAN-RENATEN network. Walter T, et al. Among authors: perrier m. J Clin Oncol. 2024 Nov 25:JCO2302724. doi: 10.1200/JCO.23.02724. Online ahead of print. J Clin Oncol. 2024. PMID: 39586038
Preliminary guidelines for the detection and management of drug-related problems in cancer patients with type 2 diabetes mellitus: a practical resource for oncology pharmacists.
Gossery C, Clarenne J, Barraud S, Brugel M, Boulin M, Carlier C, Perrier M, Botsen D, Hettler D, Kanagaratnam L, Mongaret C, Bouché O, Slimano F. Gossery C, et al. Among authors: perrier m. Support Care Cancer. 2024 Nov 14;32(12):791. doi: 10.1007/s00520-024-09014-z. Support Care Cancer. 2024. PMID: 39542931
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.
Fourati S, Reslan A, Bourret J, Casalegno JS, Rahou Y, Chollet L, Pillet S, Tremeaux P, Dossou NC, Gault E, Salmona M, Imbert-Marcille BM, Mirand A, Larrat S, Moisan A, Marot S, Schnuriger A, Veyrenche N, Engelmann I, Handala L, Henry A, Stephan V, Brichler S, Avettand-Fenoel V, Zemali N, Lefeuvre C, Pronier C, Deroche L, Jaffar-Bandjee MC, Mouna L, Francois C, Regueme A, Hartard C, Rogez S, Gallais F, Ly A, Rodriguez C, Dos Santos G, Simon-Loriere E, Schwartz O, Buchrieser J, Pawlotsky JM, Lemoine F, Audureau E, Rameix-Welti MA; POLYRES investigators. Fourati S, et al. Lancet Infect Dis. 2024 Oct 14:S1473-3099(24)00570-X. doi: 10.1016/S1473-3099(24)00570-X. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39419046
Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted-screening analysis case-control study (PESTIPAC).
Brugel M, Callon S, Carlier C, Amroun KL, Botsen D, Kianmanesh R, Perrier M, Piardi T, Renard Y, Rhaiem R, El Balkhi S, Bouché O. Brugel M, et al. Among authors: perrier m. United European Gastroenterol J. 2024 Sep;12(7):951-959. doi: 10.1002/ueg2.12602. Epub 2024 Aug 8. United European Gastroenterol J. 2024. PMID: 39118264 Free PMC article.
Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.
Fosse A, Hadoux J, Girot P, Beron A, Afchain P, Cottereau AS, Baudin E, Dierickx LO, Lecomte T, Perrier M, Lepage C, Bouhier-Leporrier K, Goichot B, Lachachi B, Walter T, Durand A. Fosse A, et al. Among authors: perrier m. J Nucl Med. 2024 Sep 3;65(9):1416-1422. doi: 10.2967/jnumed.123.267363. J Nucl Med. 2024. PMID: 39089810
Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group.
Chevalier B, Bonnet D, Lepage C, Perrier M, Borson-Chazot F, Abeillon J, Delobel JB, Jannin A, Hadoux J, Haissaguere M, Lombard-Bohas C, Walter T, Chardon L. Chevalier B, et al. Among authors: perrier m. J Endocr Soc. 2024 May 23;8(7):bvae102. doi: 10.1210/jendso/bvae102. eCollection 2024 May 23. J Endocr Soc. 2024. PMID: 38854908 Free PMC article.
240 results